참고문헌 (195)

1. Trends Pharmacol. Sci. Portoghese 10 230 1989 10.1016/0165-6147(89)90267-8 Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists 

   상세보기

2. Br. J. Pharmacol. Vauquelin 168 1771 2013 10.1111/bph.12106 Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands 

   상세보기

3. Cancer Biother. Radiopharm. Rudnick 24 155 2009 Affinity and avidity in antibody-based tumor targeting 

   상세보기

4. J. Am. Chem. Soc. Profit 121 280 1999 10.1021/ja983515n Bivalent inhibitors of protein tyrosine kinases 

   상세보기

5. Nature Rodrik-Outmezguine 534 272 2016 10.1038/nature17963 Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor 

   상세보기

6. Pharmacol. Res. Roskoski 103 26 2016 10.1016/j.phrs.2015.10.021 Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes 

   상세보기

7. Pharmacol. Ther. Wu 156 59 2015 10.1016/j.pharmthera.2015.10.002 Allosteric small-molecule kinase inhibitors 

   상세보기

8. Nature Zhang 463 501 2010 10.1038/nature08675 Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors 

   상세보기

9. Crit. Rev. Biochem. Mol. Biol. Gower 49 102 2014 10.3109/10409238.2013.875513 Bivalent inhibitors of protein kinases 

   상세보기

10. Angew. Chem. Int. Ed. Lu 59 13764 2020 10.1002/anie.201914525 New promise and opportunities for allosteric kinase inhibitors 

    상세보기

11. Drug Discov. Today Zhao 23 727 2018 10.1016/j.drudis.2018.01.035 Progress with covalent small-molecule kinase inhibitors 

    상세보기

12. Methods Mol. Biol. Restituyo 1248 95 2015 10.1007/978-1-4939-2020-4_7 A fragment-based selection approach for the discovery of peptide macrocycles targeting protein kinases 

    상세보기

13. Chembiochem Kriisa 16 312 2015 10.1002/cbic.201402526 Inhibition of CREB phosphorylation by conjugates of adenosine analogues and arginine-rich peptides, inhibitors of PKA catalytic subunit 

    상세보기

14. Bioconjugate Chem. Ivan 27 1900 2016 10.1021/acs.bioconjchem.6b00293 Bifunctional ligands for inhibition of Tight-binding protein-protein interactions 

    상세보기

15. Biochim. Biophys. Acta Protein Proteonomics Nonga 1868 2020 Discovery of strong inhibitory properties of a monoclonal antibody of PKA and use of the antibody and a competitive photoluminescent orthosteric probe for analysis of the protein kinase 

16. Biosci. Biotechnol. Biochem. Nonga 84 1839 2020 10.1080/09168451.2020.1772038 Inhibitors and fluorescent probes for protein kinase PKAcbeta and its S54L mutant, identified in a patient with cortisol producing adenoma 

    상세보기

17. ACS Omega Muller 4 775 2019 10.1021/acsomega.8b02364 Conceptional design of self-assembling bisubstrate-like inhibitors of protein kinase A resulting in a boronic acid glutamate linkage 

    상세보기

18. Biochem. J. Cozza 471 415 2015 10.1042/BJ20141127 Design, validation and efficacy of bisubstrate inhibitors specifically affecting ecto-CK2 kinase activity 

    상세보기

19. Bioconjugate Chem. Viht 26 2324 2015 10.1021/acs.bioconjchem.5b00383 Acetoxymethyl ester of Tetrabromobenzimidazole-peptoid conjugate for inhibition of protein kinase CK2 in living cells 

    상세보기

20. Sci. Rep. Winiewska-Szajewska 9 11018 2019 10.1038/s41598-019-47404-0 Rational drug-design approach supported with thermodynamic studies - a peptide leader for the efficient bi-substrate inhibitor of protein kinase CK2 

    상세보기

21. Bioorg. Chem. Pietsch 96 2020 10.1016/j.bioorg.2020.103608 Unexpected CK2beta-antagonistic functionality of bisubstrate inhibitors targeting protein kinase CK2 

    상세보기

22. ACS Med. Chem. Lett. Lechtenberg 8 726 2017 10.1021/acsmedchemlett.7b00127 Structure-guided strategy for the development of potent bivalent ERK inhibitors 

    상세보기

23. ACS Chem. Biol. Gower 11 121 2016 10.1021/acschembio.5b00847 Conversion of a single polypharmacological agent into selective bivalent inhibitors of intracellular kinase activity 

    상세보기

24. Bioorg. Med. Chem. Lett Kedika 30 2020 10.1016/j.bmcl.2020.127552 Design of a dual ERK5 kinase activation and autophosphorylation inhibitor to block cancer stem cell activity 

    상세보기

25. Bioconjugate Chem. Kestav 26 225 2015 10.1021/bc500464r Bisubstrate inhibitor approach for targeting mitotic kinase Haspin 

    상세보기

26. Acta Crystallogr F Struct Biol Commun Lavogina 72 339 2016 10.1107/S2053230X16004611 Co-crystal structures of the protein kinase haspin with bisubstrate inhibitors 

    상세보기

27. Chembiochem Kestav 18 790 2017 10.1002/cbic.201600697 Slowly on, slowly off: bisubstrate-analogue conjugates of 5-iodotubercidin and histone H3 peptide targeting protein kinase haspin 

    상세보기

28. Chembiochem Scharow 17 759 2016 10.1002/cbic.201500535 Development of bifunctional inhibitors of polo-like kinase 1 with low-nanomolar activities against the polo-box domain 

    상세보기

29. Annu. Rev. Biochem. Dar 80 769 2011 10.1146/annurev-biochem-090308-173656 The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling 

    상세보기

30. Med. Res. Rev. Fischer 37 314 2017 10.1002/med.21409 Approved and experimental small-molecule oncology kinase inhibitor drugs: a Mid-2016 Overview 

    상세보기

31. Science Klaeger 358 2017 10.1126/science.aan4368 The target landscape of clinical kinase drugs 

    상세보기

32. Pharmacol. Res. Roskoski 152 2020 10.1016/j.phrs.2019.104609 Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update 

    상세보기

33. J. Biol. Chem. Walsh 243 3763 1968 10.1016/S0021-9258(19)34204-8 An adenosine 3’,5’-monophosphate-dependant protein kinase from rabbit skeletal muscle 

    상세보기

34. Curr. Opin. Cell Biol. Walsh 4 241 1992 10.1016/0955-0674(92)90039-F Substrate diversity of the cAMP-dependent protein kinase: regulation based upon multiple binding interactions 

    상세보기

35. PLoS Biol. Zhang 13 2015 10.1371/journal.pbio.1002192 Single Turnover autophosphorylation cycle of the PKA RIIbeta holoenzyme 

    상세보기

36. Front. Biosci. Skalhegg 2 d331 1997 10.2741/A195 Specificity in the cAMP/PKA signaling pathway. differential expression, regulation, and subcellular localization of subunits of PKA 

    상세보기

37. Rev. Neurosci. Dagda 26 359 2015 10.1515/revneuro-2014-0085 Role of protein kinase A in regulating mitochondrial function and neuronal development: implications to neurodegenerative diseases 

    상세보기

38. Taylor 1461 2010 Handbook of Cell Signaling Chapter 179 - cAMP-dependent protein kinase 

39. Biochim. Biophys. Acta Taylor 1697 259 2004 10.1016/j.bbapap.2003.11.029 PKA: a portrait of protein kinase dynamics 

    상세보기

40. Biochim. Biophys. Acta Taylor 1754 25 2005 10.1016/j.bbapap.2005.08.024 Dynamics of signaling by PKA 

    상세보기

41. Physiol. Rev. Francis 91 651 2011 10.1152/physrev.00030.2010 Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions 

    상세보기

42. Nat. Rev. Mol. Cell Biol. Taylor 13 646 2012 10.1038/nrm3432 Assembly of allosteric macromolecular switches: lessons from PKA 

    상세보기

43. Science Knighton 253 407 1991 10.1126/science.1862342 Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase 

    상세보기

44. J. Med. Chem. Ricouart 34 73 1991 10.1021/jm00105a012 Design of potent protein kinase inhibitors using the bisubstrate approach 

    상세보기

45. Bioorg. Med. Chem. Lett Hines 14 2951 2004 10.1016/j.bmcl.2004.03.039 Design, synthesis, and characterization of an ATP-peptide conjugate inhibitor of protein kinase A 

    상세보기

46. Org. Lett. Schneider 7 1695 2005 10.1021/ol050179o Increasing the kinase specificity of k252a by protein surface recognition 

    상세보기

47. Med. Chem. Lett. Loog 9 1447 1999 10.1016/S0960-894X(99)00210-3 Adenosine-5’-carboxylic acid peptidyl derivatives as inhibitors of protein kinases, Bioorg 

    상세보기

48. J. Am. Chem. Soc. Meyer 129 13812 2007 10.1021/ja076197d Tethering small molecules to a phage display library: discovery of a selective bivalent inhibitor of protein kinase A 

    상세보기

49. Bioorg. Med. Chem. Shomin 17 6196 2009 10.1016/j.bmc.2009.07.056 Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): optimization and selectivity profiling 

    상세보기

50. J. Med. Chem. Enkvist 49 7150 2006 10.1021/jm0605942 Conjugation of adenosine and hexa-(D-arginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases 

    상세보기

51. J. Med. Chem. Lavogina 52 308 2009 10.1021/jm800797n Structural analysis of ARC-type inhibitor (ARC-1034) binding to protein kinase A catalytic subunit and rational design of bisubstrate analogue inhibitors of basophilic protein kinases 

    상세보기

52. ChemMedChem Lavogina 5 23 2010 10.1002/cmdc.200900252 Bisubstrate inhibitors of protein kinases: from principle to practical applications 

    상세보기

53. J. Mol. Biol. Pflug 403 66 2010 10.1016/j.jmb.2010.08.028 Diversity of bisubstrate binding modes of adenosine analogue-oligoarginine conjugates in protein kinase a and implications for protein substrate interactions 

    상세보기

54. FEBS J. Raagel 275 3608 2008 10.1111/j.1742-4658.2008.06506.x Adenosine-oligoarginine conjugate, a novel bisubstrate inhibitor, effectively dissociates the actin cytoskeleton 

    상세보기

55. J. Med. Chem. Stebbins 54 6206 2011 10.1021/jm200479c Design and characterization of a potent and selective dual ATP- and substrate-competitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor 

    상세보기

56. Curr. Pharmaceut. Des. Lamba 18 2936 2012 10.2174/138161212800672813 New directions in targeting protein kinases: Focusing upon True allosteric and bivalent inhibitors 

    

57. ACS Chem. Biol. van Wandelen 8 1479 2013 10.1021/cb300709g Cell-penetrating bisubstrate-based protein kinase C inhibitors 

    상세보기

58. Anal. Biochem. Vaasa 385 85 2009 10.1016/j.ab.2008.10.030 High-affinity bisubstrate probe for fluorescence anisotropy binding/displacement assays with protein kinases PKA and ROCK 

    상세보기

59. ACS Chem. Biol. Enkvist 6 1052 2011 10.1021/cb200120v Protein-induced long lifetime luminescence of nonmetal probes 

    상세보기

60. Anal. Biochem. Kasari 422 79 2012 10.1016/j.ab.2011.12.048 Time-gated luminescence assay using nonmetal probes for determination of protein kinase activity-based disease markers 

    상세보기

61. JCI Insight Espiard 3 2018 Activating PRKACB somatic mutation in cortisol-producing adenomas 

62. J. Biol. Chem. Burnett 211 969 1954 10.1016/S0021-9258(18)71184-8 The enzymatic phosphorylation of proteins 

    상세보기

63. J. Biol. Chem. Cochet 258 1403 1983 10.1016/S0021-9258(18)32996-X Oligomeric structure and catalytic activity of G type casein kinase. Isolation of the two subunits and renaturation experiments 

    상세보기

64. J. Biol. Chem. Shi 276 2075 2001 10.1074/jbc.M008583200 A novel casein kinase 2 alpha-subunit regulates membrane protein traffic in the human hepatoma cell line HuH-7 

    상세보기

65. Biochem. J. Litchfield 369 1 2003 10.1042/bj20021469 Protein kinase CK2: structure, regulation and role in cellular decisions of life and death 

    상세보기

66. Curr. Med. Chem. Guerra 15 1870 2008 10.2174/092986708785132933 Protein kinase CK2 in human diseases 

    상세보기

67. Cell. Mol. Life Sci. Pinna 66 1795 2009 10.1007/s00018-009-9148-9 Protein kinase CK2 in health and disease: protein kinase CK2: an ugly duckling in the kinome pond 

    상세보기

68. Cell Tissue Res. Montenarh 342 139 2010 10.1007/s00441-010-1068-3 Cellular regulators of protein kinase CK2 

    상세보기

69. J. Biol. Chem. Reed 269 18192 1994 10.1016/S0021-9258(17)32434-1 Cloning and disruption of CKB2, the gene encoding the 32-kDa regulatory beta’-subunit of Saccharomyces cerevisiae casein kinase II 

    상세보기

70. Proc. Natl. Acad. Sci. U. S. A. Sugano 95 11020 1998 10.1073/pnas.95.18.11020 Protein kinase CK2 interacts with and phosphorylates the Arabidopsis circadian clock-associated 1 protein 

    상세보기

71. FEBS Lett. Kalmykova 416 164 1997 10.1016/S0014-5793(97)01195-2 The Su(Ste) repeat in the Y chromosome and betaCK2tes gene encode predicted isoforms of regulatory beta-subunit of protein kinase CK2 in Drosophila melanogaster 

    상세보기

72. Faseb. J. Allende 9 313 1995 10.1096/fasebj.9.5.7896000 Protein kinases. 4. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation 

    상세보기

73. Histol. Histopathol. Tawfic 16 573 2001 Protein kinase CK2 signal in neoplasia 

    상세보기

74. Pharmaceuticals Cozza 10 2017 10.3390/ph10010026 The development of CK2 inhibitors: from Traditional pharmacology to in silico rational drug design 

    상세보기

75. Asian Pac. J. Cancer Prev. APJCP Lian 20 23 2019 10.31557/APJCP.2019.20.1.23 Protein kinase CK2, a potential therapeutic target in carcinoma Management 

    상세보기

76. J. Med. Chem. Pierre 54 635 2011 10.1021/jm101251q Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer 

    상세보기

77. Chembiochem Battistutta 8 1804 2007 10.1002/cbic.200700307 The ATP-binding site of protein kinase CK2 holds a positive electrostatic area and conserved water molecules 

    상세보기

78. Bioorg. Med. Chem. Schneider 20 4390 2012 10.1016/j.bmc.2012.05.038 Modified tetrahalogenated benzimidazoles with CK2 inhibitory activity are active against human prostate cancer cells LNCaP in vitro 

    상세보기

79. Faseb. J. Meggio 17 349 2003 10.1096/fj.02-0473rev One-thousand-and-one substrates of protein kinase CK2? 

    상세보기

80. Org. Biomol. Chem. Enkvist 10 8645 2012 10.1039/c2ob26022k A subnanomolar fluorescent probe for protein kinase CK2 interaction studies 

    상세보기

81. J. Biol. Chem. Kennelly 266 15555 1991 10.1016/S0021-9258(18)98436-X Consensus sequences as substrate-specificity determinants for protein-kinases and protein phosphatases 

    상세보기

82. Cell. Mol. Biol. Res. Meggio 40 401 1994 Substrate specificity of protein kinase CK2 

83. Biochim. Biophys. Acta Mol. Cell Res. Pinna 1314 191 1996 10.1016/S0167-4889(96)00083-3 How do protein kinases recognize their substrates? 

    상세보기

84. Chem. Commun. (Camb.) Ekambaram 50 4096 2014 10.1039/C3CC49198F Benzoselenadiazole-based responsive long-lifetime photoluminescent probes for protein kinases 

    상세보기

85. Bioorg. Med. Chem. Vahter 25 2277 2017 10.1016/j.bmc.2017.02.055 Oligo-aspartic acid conjugates with benzo[c][2,6]naphthyridine-8-carboxylic acid scaffold as picomolar inhibitors of CK2 

    상세보기

86. Mol. Cell Biol. Schaeffer 19 2435 1999 10.1128/MCB.19.4.2435 Mitogen-activated protein kinases: specific messages from ubiquitous messengers 

    상세보기

87. Oncogene Dhillon 26 3279 2007 10.1038/sj.onc.1210421 MAP kinase signalling pathways in cancer 

    상세보기

88. Microbiol. Mol. Biol. Rev. Cargnello 75 50 2011 10.1128/MMBR.00031-10 Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases 

    상세보기

89. Pharmacol. Res. Roskoski 66 105 2012 10.1016/j.phrs.2012.04.005 ERK1/2 MAP kinases: structure, function, and regulation 

    상세보기

90. Int. J. Mol. Sci. Stecca 20 2019 10.3390/ijms20061426 Impact of ERK5 on the hallmarks of cancer 

    상세보기

91. J. Pathol. Vakiani 223 219 2011 10.1002/path.2796 KRAS and BRAF: drug targets and predictive biomarkers 

    상세보기

92. Cancer Res Bos 49 4682 1989 Ras oncogenes in human cancer: a review 

    상세보기

93. Nature Davies 417 949 2002 10.1038/nature00766 Mutations of the BRAF gene in human cancer 

    상세보기

94. Canc. Cell Garnett 6 313 2004 10.1016/j.ccr.2004.09.022 Guilty as charged: B-RAF is a human oncogene 

    상세보기

95. Biochim. Biophys. Acta Kim 396 1802 Pathological roles of MAPK signaling pathways in human diseases 

96. Curr. Opin. Genet. Dev. Tidyman 19 230 2009 10.1016/j.gde.2009.04.001 The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation 

    상세보기

97. Curr. Opin. Pharmacol. Tanti 9 753 2009 10.1016/j.coph.2009.07.004 Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation 

    상세보기

98. Canc. Lett. Montagut 283 125 2009 10.1016/j.canlet.2009.01.022 Targeting the RAF-MEK-ERK pathway in cancer therapy 

    상세보기

99. Nat. Rev. Drug Discov. Chico 8 892 2009 10.1038/nrd2999 Targeting protein kinases in central nervous system disorders 

    상세보기

100. Clin. Sci. (Lond.) Muslin 115 203 2008 10.1042/CS20070430 MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets 

     상세보기

101. Nat. Commun. Mace 4 1681 2013 10.1038/ncomms2687 Structure of ERK2 bound to PEA-15 reveals a mechanism for rapid release of activated MAPK 

     상세보기

102. Methods Mol. Biol. Weijman 1487 53 2017 10.1007/978-1-4939-6424-6_4 Structural studies of ERK2 protein complexes 

     상세보기

103. Biochem. Biophys. Res. Commun. Ohori 336 357 2005 10.1016/j.bbrc.2005.08.082 Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex 

     상세보기

104. J. Biol. Chem. Sheridan 283 19511 2008 10.1074/jbc.M801074200 Substrate discrimination among mitogen-activated protein kinases through distinct docking sequence motifs 

     상세보기

105. Pharmacol. Res. Roskoski 142 151 2019 10.1016/j.phrs.2019.01.039 Targeting ERK1/2 protein-serine/threonine kinases in human cancers 

     상세보기

106. J. Med. Chem. Aronov 47 5616 2004 10.1021/jm049793g Toward a pharmacophore for kinase frequent hitters 

     상세보기

107. J. Am. Chem. Soc. Statsuk 130 17568 2008 10.1021/ja807066f Tuning a three-component reaction for trapping kinase substrate complexes 

     상세보기

108. Oncogene Mehta 22 1381 2003 10.1038/sj.onc.1206154 MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion 

     상세보기

109. Oncotarget Song 6 33279 2015 10.18632/oncotarget.5337 Inhibition of BMK1 pathway suppresses cancer stem cells through BNIP3 and BNIP3L 

     상세보기

110. Canc. Lett. Hoang 392 51 2017 10.1016/j.canlet.2017.01.034 Oncogenic signaling of MEK5-ERK5 

     상세보기

111. Stem Cell Reports Tusa 11 929 2018 10.1016/j.stemcr.2018.08.016 Targeting the extracellular signal-regulated kinase 5 pathway to suppress human chronic Myeloid leukemia stem cells 

     상세보기

112. Oncogene Pavan 37 4197 2018 10.1038/s41388-018-0270-8 A kinome-wide high-content siRNA screen identifies MEK5-ERK5 signaling as critical for breast cancer cell EMT and metastasis 

     상세보기

113. Cell Death Dis. Pereira 5 68 2019 10.1038/s41420-019-0150-1 MEK5/ERK5 activation regulates colon cancer stem-like cell properties 

     상세보기

114. J. Biol. Chem. Glatz 288 8596 2013 10.1074/jbc.M113.452235 Structural mechanism for the specific assembly and activation of the extracellular signal regulated kinase 5 (ERK5) module 

     상세보기

115. ACS Chem. Biol. Brandvold 7 1393 2012 10.1021/cb300172e Development of a highly selective c-Src kinase inhibitor 

     상세보기

116. Canc. Cell Yang 18 258 2010 10.1016/j.ccr.2010.08.008 Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein 

     상세보기

117. ACS Med. Chem. Lett. Deng 2 195 2011 10.1021/ml100304b Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1 

     상세보기

118. J. Med. Chem. Nguyen 62 928 2019 10.1021/acs.jmedchem.8b01606 Discovery and characterization of the potent and highly selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine based in vitro probe BAY-885 for the kinase ERK5 

     상세보기

119. Oncogene Tusa 37 2601 2018 10.1038/s41388-018-0164-9 ERK5 is activated by oncogenic BRAF and promotes melanoma growth 

     상세보기

120. Proc. Natl. Acad. Sci. U. S. A. Lin 113 11865 2016 10.1073/pnas.1609019113 ERK5 kinase activity is dispensable for cellular immune response and proliferation 

     상세보기

121. FEBS Lett. Tanaka 355 4 1994 10.1016/0014-5793(94)01155-9 Isolation and characterization of cDNA clones specifically expressed in testicular germ cells 

     상세보기

122. Protein Sci. Higgins 10 1677 2001 10.1110/ps.49901 Haspin-like proteins: a new family of evolutionarily conserved putative eukaryotic protein kinases 

     상세보기

123. Proc. Natl. Acad. Sci. U. S. A. Eswaran 106 20198 2009 10.1073/pnas.0901989106 Structure and functional characterization of the atypical human kinase haspin 

     상세보기

124. J. Cell Biol. Adams 153 865 2001 10.1083/jcb.153.4.865 Essential roles of Drosophila inner centromere protein (INCENP) and aurora B in histone H3 phosphorylation, metaphase chromosome alignment, kinetochore disjunction, and chromosome segregation 

     상세보기

125. Genes Dev. Dai 19 472 2005 10.1101/gad.1267105 The kinase haspin is required for mitotic histone H3 Thr 3 phosphorylation and normal metaphase chromosome alignment 

     상세보기

126. Mol. Cell Ghenoiu 52 734 2013 10.1016/j.molcel.2013.10.002 Autoinhibition and Polo-dependent multisite phosphorylation restrict activity of the histone H3 kinase Haspin to mitosis 

     상세보기

127. Cell. Mol. Life Sci. Higgins 60 446 2003 10.1007/s000180300038 Structure, function and evolution of haspin and haspin-related proteins, a distinctive group of eukaryotic protein kinases 

     상세보기

128. Proc. Natl. Acad. Sci. U. S. A. Villa 106 20204 2009 10.1073/pnas.0908485106 Crystal structure of the catalytic domain of Haspin, an atypical kinase implicated in chromatin organization 

     상세보기

129. Chromosoma Higgins 119 137 2010 10.1007/s00412-009-0250-4 Haspin: a newly discovered regulator of mitotic chromosome behavior 

     상세보기

130. Bioorg. Med. Chem. Lett Cuny 22 2015 2012 10.1016/j.bmcl.2012.01.028 Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors 

     상세보기

131. Fernández 2017 Tricyclic Compounds for Use as Kinase Inhibitors 

132. Bioorg. Med. Chem. Lett Enkvist 17 5336 2007 10.1016/j.bmcl.2007.08.016 Carbocyclic 3’-deoxyadenosine-based highly potent bisubstrate-analog inhibitor of basophilic protein kinases 

     상세보기

133. Mol. Cell. Proteomics Maiolica 13 1724 2014 10.1074/mcp.M113.034819 Modulation of the chromatin phosphoproteome by the Haspin protein kinase 

     상세보기

134. J. Biol. Chem. Sabers 270 815 1995 10.1074/jbc.270.2.815 Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells 

     상세보기

135. Companion Diagnostics: From Biomarker Identification to Market Entry Perl 1346 33 2015 mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging 

136. Biochim. Biophys. Acta Xu 1846 638 2014 mTOR signaling in tumorigenesis 

137. Nature Hsieh 485 55 2012 10.1038/nature10912 The translational landscape of mTOR signalling steers cancer initiation and metastasis 

     상세보기

138. Nat. Rev. Mol. Cell Biol. Barr 5 429 2004 10.1038/nrm1401 Polo-like kinases and the orchestration of cell division 

     상세보기

139. Clin. Canc. Res. Degenhardt 16 384 2010 10.1158/1078-0432.CCR-09-1380 Targeting Polo-like kinase in cancer therapy 

     상세보기

140. Mol. Cells Murugan 32 209 2011 10.1007/s10059-011-0126-3 Plk1-Targeted small molecule inhibitors: molecular basis for their potency and specificity 

     상세보기

141. ACS Chem. Biol. Brandvold 10 1387 2015 10.1021/cb501048b Exquisitely specific bisubstrate inhibitors of c-Src kinase 

     상세보기

142. Bioconjugate Chem. Johnson 27 1745 2016 10.1021/acs.bioconjchem.6b00243 Bivalent inhibitors of c-src tyrosine kinase that bind a regulatory domain 

     상세보기

143. ACS Med. Chem. Lett. Kwarcinski 6 898 2015 10.1021/acsmedchemlett.5b00167 Discovery of bivalent kinase inhibitors via enzyme-templated fragment elaboration 

     상세보기

144. Org. Biomol. Chem. Kedika 16 6443 2018 10.1039/C8OB01406J Converting a weaker ATP-binding site inhibitor into a potent hetero-bivalent ligand by tethering to a unique peptide sequence derived from the same kinase 

     상세보기

145. Expet Opin. Drug Discov. Zamecnikova 9 77 2014 10.1517/17460441.2014.865012 Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer 

     상세보기

146. Eur. J. Biochem. Radha 236 352 1996 10.1111/j.1432-1033.1996.00352.x Association of Lyn tyrosine kinase with the nuclear matrix and cell-cycle-dependent changes in matrix-associated tyrosine kinase activity 

     상세보기

147. Oncogene Robinson 19 5548 2000 10.1038/sj.onc.1203957 The protein tyrosine kinase family of the human genome 

     상세보기

148. J. Hematol. Oncol. Huang 13 143 2020 10.1186/s13045-020-00977-0 Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020) 

     상세보기

149. J. Allergy Clin. Immunol. Pandey 141 522 2018 10.1016/j.jaci.2017.07.016 Kinase inhibitors in clinical practice: an expanding world 

     상세보기

150. Proc. Natl. Acad. Sci. U. S. A. Oppermann 76 1804 1979 10.1073/pnas.76.4.1804 Uninfected vertebrate cells contain a protein that is closely related to the product of the avian sarcoma virus transforming gene (src) 

     상세보기

151. Nat. Rev. Mol. Cell Biol. Martin 2 467 2001 10.1038/35073094 The hunting of the Src 

     상세보기

152. Oncogene Bjorge 19 5620 2000 10.1038/sj.onc.1203923 Selected glimpses into the activation and function of Src kinase 

     상세보기

153. Oncogene Irby 19 5636 2000 10.1038/sj.onc.1203912 Role of Src expression and activation in human cancer 

     상세보기

154. Nat. Commun. Shukla 5 3397 2014 10.1038/ncomms4397 Activation pathway of Src kinase reveals intermediate states as targets for drug design 

     상세보기

155. Canc. Cell Ishizawar 6 209 2004 10.1016/j.ccr.2004.09.001 c-Src and cooperating partners in human cancer 

     상세보기

156. Proc. Natl. Acad. Sci. U. S. A. Cartwright 87 558 1990 10.1073/pnas.87.2.558 Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis 

     상세보기

157. Biochem. Biophys. Res. Commun. Lutz 243 503 1998 10.1006/bbrc.1997.8043 Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma 

     상세보기

158. J. Canc. Res. Clin. Oncol. Reissig 127 226 2001 10.1007/s004320000197 Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue 

     상세보기

159. Clin. Colorectal Canc. Lieu 9 89 2010 10.3816/CCC.2010.n.012 The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy 

     상세보기

160. Crit. Rev. Oncol. Hematol. Elsberger 89 343 2014 10.1016/j.critrevonc.2013.12.009 Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancer 

     상세보기

161. Oncol. Puls 16 566 2011 10.1634/theoncologist.2010-0408 Current status of SRC inhibitors in solid tumor malignancies 

     상세보기

162. Cell Songyang 72 767 1993 10.1016/0092-8674(93)90404-E SH2 domains recognize specific phosphopeptide sequences 

     상세보기

163. ACS Chem. Biol. Kwarcinski 7 1910 2012 10.1021/cb300337u Irreversible inhibitors of c-src kinase that target a nonconserved cysteine 

     상세보기

164. Front. Immunol. Darling 10 1473 2019 10.3389/fimmu.2019.01473 Emerging roles for eph receptors and ephrin ligands in immunity 

     상세보기

165. Eph Nomenclature Committee, Cell Committee 90 403 1997 Unified nomenclature for Eph family receptors and their ligands, the ephrins 

166. Growth Factors Janes 32 176 2014 10.3109/08977194.2014.982276 EphA3 biology and cancer 

     상세보기

167. J. Natl. Cancer Inst. Zhuang 104 1182 2012 10.1093/jnci/djs297 Effects of cancer-associated EPHA3 mutations on lung cancer 

     상세보기

168. Oncol. Rep. Lv 40 2408 2018 EphA3 contributes to tumor growth and angiogenesis in human gastric cancer cells 

169. Canc. Cell Day 23 238 2013 10.1016/j.ccr.2013.01.007 EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme 

     상세보기

170. Eur. J. Biochem. Meggio 234 317 1995 10.1111/j.1432-1033.1995.317_c.x Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2 

     상세보기

171. Br. J. Pharmacol. Asano 98 1091 1989 10.1111/j.1476-5381.1989.tb12652.x Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase 

     상세보기

172. Cancer Res Siddiqui-Jain 70 10288 2010 10.1158/0008-5472.CAN-10-1893 CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy 

     상세보기

173. J. Med. Chem. Ward 62 11004 2019 10.1021/acs.jmedchem.9b01295 Discovery of a potent and selective oral inhibitor of ERK1/2 (AZD0364) that is efficacious in both Monotherapy and combination therapy in Models of nonsmall cell lung cancer (NSCLC) 

     상세보기

174. Oncogene Huertas 31 1408 2012 10.1038/onc.2011.335 Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin 

     상세보기

175. Clin. Canc. Res. Zeidan 26 6132 2020 10.1158/1078-0432.CCR-20-2586 A phase ib study of onvansertib, a novel oral PLK1 inhibitor, in combination therapy for patients with relapsed or refractory acute Myeloid leukemia 

     상세보기

176. J. Med. Chem. Hennequin 49 6465 2006 10.1021/jm060434q N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor 

     상세보기

177. Trends Pharmacol. Sci. Rask-Andersen 35 604 2014 10.1016/j.tips.2014.09.007 Advances in kinase targeting: current clinical use and clinical trials 

     상세보기

178. Nat. Biotechnol. Anastassiadis 29 1039 2011 10.1038/nbt.2017 Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity 

     상세보기

179. Biochem. J. Davies 351 95 2000 10.1042/bj3510095 Specificity and mechanism of action of some commonly used protein kinase inhibitors 

     상세보기

180. Neurol. Med.-Chir. Zhao 46 421 2006 10.2176/nmc.46.421 Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage 

     상세보기

181. Behav. Neurosci. Huentelman 123 218 2009 10.1037/a0014260 Peripheral delivery of a ROCK inhibitor improves learning and working memory 

     상세보기

182. Circ. Res. Wickman 92 809 2003 10.1161/01.RES.0000066663.12256.B2 Functional roles of the rho/rho kinase pathway and protein kinase C in the regulation of cerebrovascular constriction mediated by hemoglobin: relevance to subarachnoid hemorrhage and vasospasm 

     상세보기

183. Expet Opin. Invest. Drugs Chen 22 537 2013 10.1517/13543784.2013.778242 Fasudil and its analogs: a new powerful weapon in the long war against central nervous system disorders? 

     상세보기

184. J. Immunotherap. Precision Oncology Falchook 2 10 2019 10.4103/JIPO.JIPO_17_18 Extracellular signal-regulated kinase (ERK) inhibitors in oncology clinical trials 

     상세보기

185. Biochem. Soc. Trans. Cook 48 1859 2020 10.1042/BST20190338 Small molecule ERK5 kinase inhibitors paradoxically activate ERK5 signalling: be careful what you wish for 

     상세보기

186. BioMed Res. Int. Luongo 2015 2015 10.1155/2015/676725 Chronic pain: new insights in molecular and cellular mechanisms 

     상세보기

187. Mol. Canc. Therapeut. Slotkin 14 395 2015 10.1158/1535-7163.MCT-14-0711 MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma 

     상세보기

188. Mol. Canc. Therapeut. Valsasina 11 1006 2012 10.1158/1535-7163.MCT-11-0765 NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies 

     상세보기

189. Clin. Breast Canc. Gucalp 11 306 2011 10.1016/j.clbc.2011.03.021 Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer 

     상세보기

190. Invest. N. Drugs Reddy 33 977 2015 10.1007/s10637-015-0257-z Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer 

     상세보기

191. PloS One Bottger 12 2017 10.1371/journal.pone.0178943 Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum 

     상세보기

192. Amino Acids Werle 30 351 2006 10.1007/s00726-005-0289-3 Strategies to improve plasma half life time of peptide and protein drugs 

     상세보기

193. PLoS Comput. Biol. Camacho 4 2008 10.1371/journal.pcbi.1000231 Structural and thermodynamic approach to peptide immunogenicity 

     상세보기

194. Nat. Rev. Drug Discov. Morrison 17 531 2018 10.1038/nrd.2018.125 Constrained peptides’ time to shine? 

     상세보기

195. Adv. Drug Deliv. Rev. Wang 110-111 112 2017 10.1016/j.addr.2016.06.015 Peptide-drug conjugates as effective prodrug strategies for targeted delivery 

     상세보기

활용도 Top5 논문

더보기

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.